Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 6/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.41 |
| ▸ | AURKC | Q9UQB9 | 2/20 | 0.41 |
| ▸ | RET | P07949 | 4/20 | 0.38 |
| ▸ | LCK | P06239 | 1/20 | 0.38 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16682131 | 0.87 | WDR5 (0.37) | RETMAPTTSHRCHRNA3MAPK1 | |
| SCHEMBL16675932 | 0.84 | EGFR (0.42) | AURKAAURKBAURKCRETLCK | |
| SCHEMBL16675905 | 0.83 | MAPK1 (0.45) | AURKAAURKBAURKCRETLCK | |
| SCHEMBL16675900 | 0.82 | JAK3 (0.36) | AURKAAURKBRETLCKSRC | |
| SCHEMBL16675909 | 0.78 | PAK4 (0.39) | AURKAAURKBAURKCRETLCK | |
| SCHEMBL16675946 | 0.77 | KDM4E (0.41) | MAPTTSHRMAPK1 | |
| SCHEMBL16682133 | 0.72 | EGFR (0.40) | RETLCKSRCCHRNA3EGFR | |
| SCHEMBL16682118 | 0.71 | MAPK1 (0.42) | RETMAPTCHRNA3MAPK1EGFR | |
| SCHEMBL16675902 | 0.69 | CCNA2 (0.38) | AURKAAURKBRETLCKSRC | |
| SCHEMBL16675921 | 0.67 | CCNA2 (0.40) | RETLCKSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9580391-B2 | Saturated acyl guanidine for inhibition of F1F0-ATPase | LYCERA CORPORATION (US) | 2017-02-28 | — | — | US | disclosed |
| US-20150119439-A1 | SATURATED ACYL GUANIDINE FOR INHIBITION OF F1F0-ATPASE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2015-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119439-A1 | SATURATED ACYL GUANIDINE FOR INHIBITION OF F1F0-ATPASE | ATP5F1A, ATP5F1D, ATP5F1C | AURKA 1571/4885AURKB 1274/4885AURKC 1467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.